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Resumo  
O osso é um tecido metabolicamente ativo e a sua remodelação é importante para 
regular e manter a massa óssea. Esse processo envolve a reabsorção do material ósseo por 
ação dos osteoclastos e a síntese de novo material ósseo mediado pelos osteoblastos. 
Vários estudos têm sugerido que a pressão arterial elevada está associada a 
alterações no metabolismo do cálcio, o que leva ao aumento da perda de cálcio e da 
remoção de cálcio do osso. Embora as alterações no metabolismo ósseo sejam um efeito 
adverso associado a alguns fármacos antihipertensores, o conhecimento em relação a este 
efeito terapêutico ligado com os bloqueadores de canais de cálcio é ainda muito escasso. 
Uma vez que os possíveis efeitos no osso podem ser atribuídos à ação antihipertensiva 
dessas moléculas, ou através de um efeito direto nas atividades metabólicas ósseas, torna-
se necessário esclarecer este assunto. 
Devido ao facto de que as alterações no metabolismo ósseo são um efeito adverso 
associado a alguns fármacos antihipertensores, o objetivo deste trabalho é avaliar o efeito 
que os bloqueadores dos canais de cálcio exercem sobre as células ósseas humanas, 
nomeadamente osteoclastos, osteoblastos e co-culturas de ambos os tipos celulares.  
Verificou-se que os efeitos dos fármacos antihipertensores variaram consoante o 
fármaco testado e o sistema de cultura usado. Alguns fármacos revelaram a capacidade de 
estimular a osteoclastogénese e a osteoblastogénese em concentrações baixas. 
Independentemente da identidade do fármaco, concentrações elevadas revelaram ser 
prejudiciais para a resposta das células ósseas. Os mecanismos intracelulares através dos 
quais os efeitos foram exercidos foram igualmente afetados de forma diferencial pelos 
diferentes fármacos. 
Em resumo, este trabalho demonstrou que os bloqueadores dos canais de cálcio 
utilizados possuem a capacidade de afetar direta- e indiretamente a resposta de células 
ósseas humanas, cultivadas isoladamente ou co-cultivadas. Este tipo de informação é 
crucial para compreender e prevenir os potenciais efeitos destes fármacos no tecido ósseo, 
e também para adequar e eventualmente melhorar a terapêutica antihipertensora de cada 
paciente. 
 
Palavras-chave: metabolismo ósseo, osteoblastogénese, osteoclastogénese, fármacos 
antihipertensores, bloqueadores de canais de cálcio, co-culturas  
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Abstract  
Bone is a metabolically active tissue and its remodeling is important to regulate and 
maintain bone mass. That process involves the resorption of bone material by action of 
osteoclasts, and synthesis of new bone material, mediated by osteoblasts. 
Several studies have suggested that high blood pressure is associated with changes 
in the calcium metabolism, which leads to increased calcium loss and increased calcium 
removal from bone. Although changes in bone metabolism are one side-effect associated 
with some AHDs, the knowledge regarding this effect associated with calcium channel 
blockers therapeutics is still very scarce. Since possible bone effects can be attributed to 
the antihypertensive action of those molecules, or by a direct effect on bone metabolic 
activities, a clarification about this issue is of the utmost importance.   
Due to the fact that changes in bone metabolism are one side-effect associated with 
some AHDs, the aim of this work is to assess the effects that calcium channel blockers 
exert on human bone cells, namely, osteoclasts, osteoblasts and co-cultures of both cell 
types.  
It was observed that the effects of AHDs varied among the different tested 
molecules and the used cell culture system. Some drugs revealed the ability to stimulate 
osteoclastogenesis and osteoblastogenesis at low doses. Despite the identity of the 
molecule, high concentrations of AHDs were negative for the bone cells response. The 
intracellular mechanisms through which the effects were exerted were also differentially 
affected by the different AHDs.  
In summary, this work demonstrated that calcium channel blockers have the ability 
to affect directly and indirectly the behavior of human bone cells, cultured isolated or co-
cultured. This information is crucial to understand and prevent the potential effects of 
AHDs in bone tissue and also to adjust and eventually improve the antihypertensive 
therapy given to each patient. 
 
 Keywords: bone metabolism, osteoblastogenesis, osteoclastogenesis, antihypertensive 
drugs, calcium channel blockers, co-cultures 
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Introduction 
 
Bone is a characteristic tissue of all vertebrates, essential for the protection of inner 
organs and functioning as a support for body structures. It provides rigidity and shape, 
allows the cerebral and pulmonary function, locomotion, supports haematopoiesis in the 
bone marrow, fixation of the muscles and storage of minerals (calcium, phosphate), having 
the capacity to mobilize mineral reserves quickly, if necessary, in order to maintain 
calcium homeostasis (1,2). Bone is a metabolically active tissue, highly vascularized, able 
to adapt its structure to mechanical stimuli and to repair structural damage through the 
remodeling process. Bone remodeling is important to regulate and maintain bone mass, and 
involves the resorption of bone material by action of osteoclasts and synthesis of new bone 
material, mediated by osteoblasts (1–3). Thus, large changes in their structure due to injury 
or disease can alter the equilibrium between both activities in the body and, consequently, 
compromise the quality of life of individuals. The rate of bone turnover, structure and 
composition of the collagen matrix, size, structure, density and geometry combine to 
determine the general mechanical properties of bone. Defects in these parameters will 
result in pathologies. In order to ensure an adequate bone strength, the process of bone 
turnover should be regulated carefully (4,5).  
Several studies have suggested that high blood pressure is associated with 
abnormalities in the calcium metabolism, which leads to increased calcium loss and 
increased calcium removal from bone. Since various antihypertensive agents are used for 
the treatment of hypertension, and despite the fact that it has not been fully clarified if the 
arterial hypertension is a risk factor for low bone mass and / or fractures, it is important to 
investigate the interference of these drugs on bone metabolism (6–9). Some categories of 
antihypertensive drugs (AHDs) have been reported to increase bone mineral density and 
reduce the risk of fractures (7,10). Though, the question is whether these molecules have a 
specific direct or indirect effect on bone tissue, due to the blood pressure decrease and the 
consequential effects on calcium metabolism associated with hypertension. In this context, 
it has been shown that people using certain AHDs have a lower fracture risk than the 
general population, which favors the hypothesis that AHDs may have a direct effect on 
bone cells (7,10–19). 
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Due to the high incidence of hypertension in the world and the high frequency of 
use of AHDs, particularly calcium channel blockers, it is necessary to study their influence 
on bone metabolism. Being bone disease very common and fractures a problem 
particularly relevant in the elderly, and given the incidence of hypertension, a detailed 
knowledge of the association of the two is imperative in order to improve the quality of life 
of patients. 
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CHAPTER I 
 
State of Art  
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1.1 Bone  
The bone is a specialized connective tissue with a biphasic structure consisting of 
an extracellular inorganic phase and an organic phase comprising bone cells and the 
extracellular organic matrix. The inorganic phase is mainly composed of calcium and 
phosphate, being the hydroxyapatite [Ca10(PO4)6(OH)2] form the most important one. It 
has also other ions in smaller quantities, such as silicon, for example (2,20). The inorganic 
phase has two major biological functions: the ability to resist to external and internal forces 
which the bone is subjected, preserving the shape of the body as a whole and protecting 
vital organs and it is also a reservoir of ions. The organic phase of bone matrix comprises 
25-30% of the total bone mass (21,22) and performs a variety of functions, deeply 
influencing the structure and also the mechanical and biochemical properties of the tissue. 
The main structural component of the organic phase is collagen type I (COL1) (fibrous), 
representing about 90% of the proteins of the bone (2); the remaining 10% consist in a 
variety of smaller non-structural proteins, including osteonectin, osteocalcin, 
phosphoproteins, sialoprotein, growth factors and blood proteins (2,20). 
As the load support structure of the body, the bone is formed from a combination of 
compact and cancellous bone, which is strengthened in pressure points (20,21). The 
compact bone is responsible for the stability of the skeleton, with a solid, essentially non-
porous structure (3). It is present in long, short and flat bones and contains many units in 
the form of cylinders, called osteons (5,21). The osteocytes (bone cells) are found in small 
gaps between the concentric layers of the matrix, called lamellae. The matrix contains 
collagen fibers and mineral deposits, especially calcium and phosphate. In contrast, the 
cancellous bone is arranged in a porous pattern. It contains numerous bars and plates called 
trabeculae, which follow lines of stress. The cancellous bone ensures the elasticity and 
stability of the skeleton and contributes with about 70% of the total bone metabolism (2). 
This type of bone houses a large proportion of bone marrow and is essentially present in 
the metaphysis of long bones, vertebral and iliac crest (2,5,21).  
 
1.2 Bone cells  
The bone has three main types of cells: osteoblasts and osteoclasts, whose functions 
are closely linked, and osteocytes (23). The osteoblasts and osteoclasts work in a 
coordinated way, with their activities of bone formation and resorption, respectively, to 
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carry out the growth, repair and remodeling of bone tissue (5,24). In order to the balance 
formation and bone resorption in healthy individuals, osteoblasts secrete factors that 
regulate the differentiation of osteoclasts and osteocytes secrete factors that regulate the 
activity of both osteoblasts and osteoclasts (5,24,25). Bone responds to calcium-dependent 
signals from the parathyroid gland and via vitamin D metabolites. Osteoblasts deposit 
calcium phosphate crystals by mechanisms including phosphate and calcium transport 
associated with alkalinization, in order to neutralize the acid liberated by mineral 
deposition. Calcium mobilization by osteoclasts is mediated by acid secretion. Both bone 
forming and bone resorbing cells utilize calcium signals as regulators of differentiation and 
activity (26,27). 
 
1.2.1 Osteoblasts 
Osteoblasts descend from mesenchymal progenitor cells and have a major role in 
creating and maintaining the architecture of the skeleton. They are specialized 
mononuclear cells responsible for the deposition of bone matrix and for the regulation of 
the differentiation and function of osteoclasts (23,28). Histologically, the active osteoblasts 
appear as large cuboidal cells on the bone surface, with a visible prominent rough 
endoplasmic reticulum and Golgi complex. When active, they express high levels of 
alkaline phosphatase (ALP), which is thought to be important in the bone mineralization 
process (20,23,25,28). These cells express receptors for many hormones including 1,25-
dihydroxyvitamin D, sex steroids and corticosteroids (20). In the process of osteoblasts 
maturation, several genes, such as core binding factor a1 (Cbfa1), also known as Runx2, 
and Osterix (OSX) play an important role (23). Besides these, the Wnt / β-catenin pathway 
plays a role not only in the osteoblasts differentiation, but also in their proliferation 
(1,2,4,20,24,25). After termination of the bone matrix synthesis, osteoblast cells may be 
subjected to cell death by apoptosis (programmed cell death) or differentiate into 
osteocytes or bone lining cells (23).  
 Osteoblasts are also a key element in the regulation of bone resorption by the 
expression of several modulators of osteoclastogenesis, in particular the receptor activator 
of nuclear factor kappa B (NF-kB) ligand (RANKL), which binds to its receptor RANK, 
expressed on the surface of pre-osteoclastic cells, inducing their differentiation and fusion. 
The importance of this RANKL-RANK interaction in the osteoclastogenic process is 
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highlighted by the fact that in combination with macrophage colony stimulating factor (M-
CSF), it is sufficient to promote osteoclastogenesis in vitro (23). Some hormones, 
cytokines and humoral factors may affect calcium homeostasis and bone density by 
inducing the expression of RANKL inside the osteoblasts. Among the factors that activate 
bone remodeling, vitamin D is known to induce the increase of bone resorption and 
hypercalcemia in serum. The response of osteoblasts to vitamin D may vary depending on 
the stage of differentiation of these cells: immature cells respond in a pro-osteoclastic 
resorbing activity, evidenced by an increase in the expression of RANKL; on the other 
hand, mature cells are mainly associated with an osteogenic response. Both osteoblastic 
cellular behaviors can be regulated by circulating levels of vitamin D in vivo (26,27). 
Moreover, osteoblasts secrete a dimeric glycoprotein (osteoprotegerin - OPG), 
which acts as a soluble decoy receptor for RANKL, blocking RANKL-RANK interaction 
and thereby inhibiting osteoclastogenesis and bone resorption (23).  
Overall, the major osteoblastic markers include ALP, COL1, osteocalcin, bone 
sialoprotein, bone morphogenetic protein 2 (BMP-2), RANKL and OPG (5,23,25). 
 
1.2.2 Osteocytes  
The quiescent bone surfaces are covered by an almost continuous single layer of 
inactive flattened osteoblasts, which are found dispersed throughout the bone matrix, often 
referred as bone lining cells (5). The osteocytes are osteoblasts that became sequestered 
during bone matrix synthesis, being characterized by its inability to secrete osteoid. The 
osteocytes are the most abundant cells in the bone, comprising more than 90% of the bone 
cells (5). They communicate with each other and with the surroundings through extensions 
of their plasma membrane. The bone matrix isolates osteocytes from each other and in 
order to circumvent that situation, osteocytes interact with other osteocytes and bone cells 
by an elaborate network of dendritic processes, which run inside lacunar cannaliculi 
(5,20,23).  
Despite their relative inactivity compared with osteoblasts, osteocytes play a central 
role in the determination and maintenance of bone structure. Those processes may have the 
potential to stimulate either bone resorption or synthesis. The osteocytes act as stress 
sensors, detect mechanical stress and respond to biochemical stimuli, instructing 
osteoclasts in bone resorption and osteoblasts in bone formation (5,20,23).  
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1.2.3 Osteoclasts  
Osteoclasts are mobile large multinucleated cells that play an essential role in bone 
homeostasis. They descended from the monocyte / macrophage CD14+ lineage, 
responsible for the function of resorption of bone matrix (5,29,30). These cells are formed 
by fusion of mononuclear precursors derived from pluripotent hematopoietic stem cells 
and subsequent differentiation along the surface of the bone, a process designated 
osteoclastogenesis. These precursors are found not only in bone marrow, but also in the 
peripheral blood circulation (5,20,30–33). The osteoclasts form resorption sites, adhering 
firmly to the bone surface, where they secrete protons to dissolve the mineral phase and 
proteolytic enzymes, especially cathepsin K (CATK), and tartrate-resistant acid 
phosphatase (TRAP) to degrade the collagenous matrix (5,33). The mature osteoclasts 
express receptors for various signaling molecules, including calcitonin and prostaglandins 
(20). 
The osteoclastogenesis is a complex process dependent on the action of various 
hormones, growth factors, and others, involving multiple intracellular signaling pathways, 
and is regulated by many other cytokines and by intracellular signals, including Ca
2+
 
(30,32). Vitamin D induces osteoclast differentiation, which occurs mainly as a 
consequence of the binding of RANKL to RANK, expressed on the membrane of 
hematopoietic cells, in the presence of M-CSF. Osteoclasts act on bone remodeling, in 
addition to acting in resorption and release of calcium into the organism. Bone remodeling 
occurs continuously throughout life, and in order to maintain proper serum calcium 
concentrations, it is necessary to assure that the mechanism of bone resorption will be 
controlled, and vitamin D has an important role in that process (26,27,34).  
The mature osteoclast is activated by signals, which leads to the beginning of bone 
remodeling. The osteoclast cell body is polarized, and in response to its activators, it 
undergoes internal structural changes that prepare the bone to be reabsorbed, such as actin 
cytoskeletal rearrangements and the formation of a tight junction between the surface of 
bone and the basement membrane, in order to create a sealed compartment. This external 
vacuole is then acidified by the export of hydrogen ions and the lytic enzymes TRAP and 
CATK are secreted to the resorption lacunae. Through this process the osteoclast erodes 
and degrades the underlying bone (5,29–33). 
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As noted above, there are two factors that play a central role in osteoclast 
development, whose are sufficient to promote osteoclastogenesis in vitro, the M-CSF and 
RANKL. The M-CSF is critical for the survival and proliferation of the progenitors of 
osteoclasts, while RANKL directly controls the differentiation process, interacting and 
activating RANK. The main osteoclastic markers include TRAP, CATK, carbonic 
anhydrase 2, vitronectin receptors (VNR), calcitonin receptors (CTR) and actin rings 
(5,29,31,33,35,36). 
 
1.3 Bone remodeling 
During the adult life, the skeleton suffers a continuous process of repair and 
renewal. Once formed, the bone is submitted to a process called bone remodeling, which 
involves resorption and synthesis of bone. This process occurs in micro scale along the 
skeleton, in the basic microscopic multicellular, in response to a variety of stimuli (2,4,20). 
Imbalances in the process of bone remodeling can result in serious disturbances in skeletal 
structure and function, potentially increasing morbidity and shortening life. Most bone 
diseases in adults are due to excessive osteoclast activity leading to an imbalance in the 
process that promotes resorption (1,2,4,20,24,37,38). As mentioned above, osteocytes have 
a central role in triggering and regulating bone remodeling. These cells detect 
microfissures, mechanical pressure and changes in the hormonal environment of bone and 
communicate with bone cells, which initiate bone resorption and formation (24). 
A bone remodeling cycle consists of four distinct and sequential phases: activation, 
resorption, reversal and formation (25). During the activation phase, osteoclastic 
precursors are recruited from the bloodstream and bone marrow, adhere to bone and 
differentiate into active osteoclasts that begin the process of resorption. The action of 
osteoclasts is closely related to its interaction with bone matrix proteins, including 
osteopontin and bone sialoprotein, which were secreted by osteoblasts during the previous 
cycle of bone formation (25). When resorption is complete, the reversal phase begins: the 
osteoclasts secrete signals that promote migration and differentiation of osteoblastic 
precursors, and die by apoptosis. Osteoblastic precursors proliferate locally and 
differentiate into mature osteoblasts. They migrate to the resorption lacunae formed by the 
osteoclasts. The formation phase continues with the synthesis of new bone material by 
osteoblasts until the resorbed tissue is completely replaced (1,2,4,20,24,38). 
Effects of antihypertensive drugs in the differentiation and activation of human bone cells 
 
10 
 
1.4 Hypertension  
Arterial hypertension is a major risk factor for coronary heart disease, heart failure, 
stroke and nephroangiosclerosis. Adopting a healthy lifestyle can prevent the onset and the 
development of the disease and its risk of incidence can be reduced by early detection and 
monitoring. The arterial hypertension corresponds to all situations where it is present 
increased values of blood pressure. Thus, values of systolic blood pressure greater than or 
equal to 140 mm Hg (millimeters of mercury) and / or diastolic blood pressure values 
above 90 mmHg are considered for the characterization of this condition (39). In most 
cases, there is no known cause for the arterial hypertension, although in some situations it 
is possible to identify an associated disease which is the true cause of the hypertension. 
Generally, the older the person is, the greater the probability of developing hypertension 
(39,40).  
Presently, it is thought that the worldwide prevalence of hypertension in the adult 
population is about 25 to 30% (about 1000 million people), increasing in individuals aged 
over 60 years, and accounting for about 7.6 million deaths per year and 7 million 
premature deaths. Directly associated with high blood pressure are several risk factors, 
such as age, race, obesity, tobacco use, excessive alcohol or a sedentary lifestyle. In turn, 
the arterial hypertension appears as a modifiable risk factor associated with cardiovascular 
disease (41). 
In Portugal, there are approximately two million of hypertensive people. Of these, 
only half is aware of having high blood pressure, only a quarter are medicated and only 
16% have the situation under control (39). 
In this context, antihypertensive molecules represent an important class of drugs for 
the prevention of the high morbidity and mortality associated with arterial hypertension. 
Currently there are many drugs effective in reducing the blood pressure (39,40). 
  
1.5 Antihypertensive drugs 
Adopting healthy lifestyles is an important factor for the decrease of blood pressure 
values. However, these changes are not always enough, and therefore the use of AHDs is 
often inevitable. The aim of antihypertensive therapy is to make the diastolic pressure to 
remain below 90 mmHg, without compromising renal, myocardial or cerebral function, 
without producing adverse reactions (42). 
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The AHDs can be classified, according to its main mechanism of action, in six 
major groups: diuretics, angiotensin renin modifiers, calcium channel blockers, depressants 
of adrenergic activity, direct vasodilators and others (42). 
After studying the possible causes and factors of comorbidity, treatment of a 
hypertension should start with a single drug in low initial dose, which may be 
progressively increased until obtaining the desired effect or the appearance of adverse 
reactions. The initial choice of an AHDs should fall on one considered as a first line drug. 
First-line therapy refers to the initial or first treatment given when someone is diagnosed 
with a particular disease or condition. It is considered the most effective treatment. If it is 
needed to associate two drugs, the association still must focus, when possible, on two first 
line molecules. The individual situation of the patient influences the choice of the 
appropriate AHD (42). 
 
1.5.1 Calcium channel blockers 
The calcium channel blockers are considered one of the first line AHDs. Metabolic 
significant adverse effects do not occur with their use, especially in the lipid profile. These 
drugs act preventing the entry of calcium into cells, inhibiting the flow of calcium into the 
cardiac smooth muscle cells and competitively blocking the entry of calcium through the 
slower channels present in the cytoplasmic membranes (43). Their main actions are 
conducted in smooth cells of blood vessels (by inhibiting the contraction of vascular 
smooth muscle), cardiac cells (inhibition of cardiac conduction, particularly in the 
sinoatrial and atrioventricular nodes, where conduction is dependent calcium flux) and 
hemodynamics (42–44). 
There are essentially three types of calcium channel blocker drugs, which present 
pharmacodynamic differences with significant clinical translation: dihydropyridines, 
fenilalquilamines and benzothiazepines. The dihydropyridines have higher affinity to the 
vessels resulting in systemic and coronary vasodilation, the fenilalquilamines decrease 
heart rate and atrioventricular conduction and benzothiazepines are in an intermediate 
position between them (42–44). 
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1.6 Antihypertensive drugs and bone metabolism 
Several changes in calcium metabolism have been reported in hypertension. The 
final effect of such changes is an alteration of bone mass and bone quality. A decrease of 
bone mineral density is related to hypertension. In fact, it appears as one of the major 
cardiovascular risk factors for fractures (10,45–47). AHDs can have an indirect impact on 
osteoporosis by improving the negative effects of high blood pressure as well as direct 
effects on bone metabolism, strength, and density. Calcium has a central role in bone 
strength and in the balance between osteoblastic and osteoclastic activities, the basis of the 
bone remodeling process. (10).  
Previous studies demonstrate an increase in bone mineral density and reduced 
fracture risk in patients taking antihypertensive diuretics (9,11). These may act directly on 
the cells involved in bone metabolism or indirectly by decreasing calcium excretion in 
urine. In the kidney, diuretics block sodium and chloride resorption. This effect causes an 
exchange of sodium and calcium, by promoting calcium influx and efflux of sodium (7–
9,11,12). 
The antihypertensive beta-blockers exert an effect on bone remodeling through the 
sympathetic nervous system. Most studies have shown a decreased risk of fracture, but 
there are also studies that show the existence of a neuronal network initiated by leptin that 
inhibits osteoblast activity and increases the function of osteoclasts (8,9). Also, 
contradictory results have been reported about the effects on bone mineral density (7–9). 
Angiotensin II is able to act on cells involved in bone metabolism, indirectly by 
controlling the flow on capillaries in the bone marrow or directly via receptors located in 
osteoblasts, which promote the release of mediators that in turn activate osteoclastic cells 
(9,15). At the level of osteoblasts, it stimulates DNA synthesis, cell proliferation, collagen 
synthesis by the precursors of the osteoblasts and decreases the mineralization promoted by 
mature osteoblasts (15). The use of inhibitors of angiotensin-converting enzyme has been 
associated with a decreased risk of fracture or improving bone metabolism (7–9,15,16). 
 
1.6.1 In vitro studies using calcium channel blockers  
Results of in vitro studies have shown that calcium channel blockers may also 
affect bone cells (8), but few data are currently available about this issue. Calcium channel 
blockers inhibit calcium influx through calcium channel L-type voltage-dependent at the 
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level of vascular smooth muscle, thus interrupting the contraction process. As mentioned 
above, during their differentiation, osteoblasts express ALP, COL1 and other bone matrix 
proteins, forming a mineralized bone matrix. During the process, osteoblasts rely in come 
mechanisms that involve the action of voltage-dependent calcium channels (6). In addition, 
several bone regulatory factors, such as vitamin D3, parathyroid hormone and 
prostaglandin E2 cause an increase in the concentration of intracellular calcium, part of 
which is decreased by dihydropyridine, one type of calcium channel blocker (6). These 
factors also promote or inhibit differentiation of osteoblasts. Therefore, it is noted that 
signaling through calcium channel L-type may be important for the function of osteoblasts 
(6–9). With respect to osteoclasts, the molecular and cellular effect of calcium channel 
blockers remains unclear. 
The effect of calcium channel blockers on bone metabolism was examined in the 
1990s in a few studies with a small number of experimental subjects (10 ≤ n ≤ 20) (10). 
The collected data have not revealed any considerable effect of calcium antagonists on 
bone metabolism. However, in view of the fact that the number of experimental subjects 
was small, it is not possible to exclude an effect of calcium channel blockers on the 
indicators of bone tissue homeostasis. Regarding this, one of the assumptions is that long-
term use of calcium channel blockers can be associated with osteoporosis, due to a decline 
of bone marrow perfusion, observed in healthy volunteers (10,19). On the other hand, no 
evidence was found regarding an altered fracture risk in users of calcium channel blockers, 
in a case–control fracture study (10,18). However, in a pharmacoepidemiological study, 
conducted in the general population with a larger number of experimental subjects, 
calcium channel blockers reduced the risk of fractures by 6 % (adjusted OR = 0.94, 95 % 
CI 0.91–0.96). The decreased risk was higher with the use of calcium channel blockers that 
are not related to dihydropyridine (10,17).  
Some studies addressed the effect of amlodipine on bone metabolism in male albino 
Wistar rats (13) and the effects of different amlodipine and lacidipine doses on 
ovariectomized rat femurs' calcium and phosphor content (14). In the first one, exerted an 
effect on bone metabolism. The results indicate that amlodipine treatment in the long-term 
administration of amlodipine at a dose of 0.3 mg/100 g body weight may induce 
deceleration of bone metabolism. The expression of BMP-2 in proximal tibia was 
investigated by means of immunoblotting, and bone mineral density was measured by 
Dual-energy X-ray Absorptiometry in lumbar and caudal vertebrae and in femoral areas. 
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Mechanical properties of the femurs were measured by three-point bending of the shaft and 
compression testing of the femoral neck. The experiment was performed on outbred rats 
(13). The second one highlighted the potential beneficial effects of calcium channel 
blockers in the prevention of bone loss induced by ovariectomy. For that, the study 
investigated the effects of different doses of amlodipine and lacidipine on ovariectomized 
rat femurs' calcium and phosphor content. These drugs decreased the bone loss in an 
ovariectomy-induced osteopenic rat model. Bone calcium and phosphor concentration was 
measured by a Wavelength Dispersive Spectrometer. The findings in this study suggest 
that potent calcium channel blockers, such as amlodipine and lacidipine, may have a 
beneficial effect on bone metabolism, in addition to their well-established antihypertensive 
effect (14).  
Due to the scarcity of the available information, the effects of calcium channel 
blockers on bone can not be ruled out. Furthermore, the data available was essentially 
obtained by clinical studies, without information regarding the molecular and cellular 
processes that are the basis of bone metabolism. Finally, the published reports present 
some limitations that further impair the establishment of precise considerations about this 
issue. Namely, the experimental subjects were heterogeneous in terms of patient age, sex, 
comorbidities, and ethnic origin. In addition, the effect of a particularly antihypertensive 
on bone may depend on the time of their use. Finally, the articles reviewed included 
different types of studies ranging from randomized clinical trials to 
pharmacoepidemiological studies (10). 
 Undoubtedly, more research is required in order to characterize the possible 
positive or negative effects of calcium channel blockers on bone metabolism. 
On the basis of the previous considerations, the plan of the present project was to 
study the effects of antihypertensive calcium channel blockers (amlodipine, felodipine, 
diltiazem, lercanidipine and nifedipine) in human bone cells and it has focused on the 
influence of some factors on osteoclastogenic and osteoblastogenic process. It aimed to 
characterize how AHDs affect the differentiation and function of cultured human 
osteoblastic and osteoclastic cells, cultured isolated and co-cultured. Finally, it was also 
intended to analyze the influence of several signaling pathways important for 
osteoclastogenesis and osteoblastogenesis in the cellular responses to the tested drugs. For 
that, the minimum concentration of each AHD that elicited a significant effect on analyzed 
parameters was chosen. 
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CHAPTER II 
 
Material and Methods 
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2.1 Cell Cultures  
 
2.1.1 Osteoclast cell cultures 
Peripheral blood mononuclear cells (PBMC), used as osteoclast precursor cells, 
were isolated from blood of 25-35 years old healthy male donors, after informed consent. 
After dilution with phosphate-buffered saline (PBS) (2:1), blood was applied on top of 
Ficoll-Paque™ PREMIUM (GE Healthcare Bio-Sciences). Samples were centrifuged at 
400 g for 30 minutes and PBMC were collected at the interface between Ficoll-Paque and 
PBS. Cells were washed twice with PBS. On average, for each 90 mL of processed blood 
about 450x10
6
 PBMC were obtained. PBMC, seeded at 5x10
5
 cells/cm
2
, were maintained 
in α-minimal essential medium (α-MEM) supplemented with 30% human serum (from 
the same donor from which PBMC were collected), 100 IU/ml penicillin, 2.5 μg/ml 
streptomycin, 2.5 μg/ml amphotericin B, 2 mM L-glutamine, and 25 ng/mL M-CSF and 40 
ng/mL RANKL (osteoclastogenic enhancers, (29,33,35,36)). Cell cultures were maintained 
in the absence (control) or in the presence of 10
-8
-10
-4
 M of different AHDs (which include 
plasma concentration) and they were characterized throughout a 21 day period, at days 7, 
14 and 21, for TRAP activity, total protein content, number of TRAP+ multinucleated 
cells, presence of cells with actin rings and expressing vitronectin and calcitonin receptors 
and apoptosis rate. Following, PBMC were treated with the minimum concentration of 
each AHD that elicited a significant effect on those parameters, and were further 
characterized for the expression of osteoclast-related genes, calcium phosphate resorbing 
ability and for the involvement of some osteoclastogenesis-related signalling pathways on 
cellular response. The AHDs tested - amlodipine, felodipine, diltiazem, lercanidipine and 
nifedipine - were renewed at each medium change, once a week. Cell cultures were 
incubated in a 5% CO2 humidified atmosphere at 37ºC.  
 
2.1.2  Osteoblast cell cultures 
Osteoblasts were obtained from femur heads of patients (25-45 years old) 
undergoing orthopaedic surgery procedures, after informed consent. Briefly, bone was 
broken in small pieces, which were maintained in α-MEM supplemented with 10% fetal 
bovine serum, 100 IU/ml penicillin, 2.5 μg/ml streptomycin, 2.5 μg/ml amphotericin B and 
50 μg/mL ascorbic acid. After reaching about 70% of confluence, cells were detached with 
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0.05% trypsin and 0.5 mM ethylenediamine tetraacetic acid (EDTA), and were seeded at 
10
4
 cells/cm
2
. Cell cultures, performed in the same culture medium mentioned above, were 
treated with 10 mM β-glycerophosphate and were maintained in the absence (control) or in 
the presence of 10
-8
-10
-4
 M (which include plasma concentration) of different AHDs. Cells 
were characterized throughout a 21 day period, at days 7, 14 and 21, for cellular 
proliferation/viability, ALP activity, total protein content, histochemical staining of ALP 
and phosphate deposits, staining of actin and nuclei and apoptosis rate. Following, 
osteoblasts were treated with the minimum concentration of each AHD that elicited a 
significant effect on those parameters, and were further characterized for the expression of 
osteoblast-related genes and for the involvement of some osteoblastogenesis-related 
signalling pathways on cellular response. Cultures were incubated at 37ºC in a 5% CO2 
humidified atmosphere and the culture medium was replaced once a week.  
 
2.1.3 Co-cultures of osteoblasts and osteoclasts 
Osteoblasts were seeded at 10
3
 cells/cm
2
 and were incubated for 24h in α-MEM, 
supplemented with 10% fetal bovine serum, 100 IU/ml penicillin, 2.5 μg/ml streptomycin, 
2.5 μg/ml amphotericin B and 50 μg/ml ascorbic acid. After that, PBMC were added at 
5x10
5
 cells/cm
2
 to the osteoblasts and co-cultures were maintained in α-MEM 
supplemented with 20% human serum (from the same donor where PBMC were obtained), 
100 IU/ml penicillin, 2.5 μg/ml streptomycin, 2.5 μg/ml amphotericin B and 2 mM L-
glutamine. Cell cultures were maintained in the absence (control) or in the presence of 10
-
8
-10
-4
 M (which include plasma concentration) of different AHDs and they were 
characterized throughout a 21 day period, at days 7, 14 and 21. Cellular response was 
assessed through the same osteoclast and osteoblast parameters mentioned above for the 
corresponding isolated cell cultures. Cultures were maintained in a 5% CO2 humidified 
atmosphere at 37ºC for 21 days. Culture medium was replaced once a week and the AHDs 
were renewed at each medium change. 
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2.2 Characterization of cell cultures 
  
2.2.1 Total protein content 
 Cellular protein content was quantified by Bradford’s method (48). Cell cultures 
were washed twice with PBS and solubilized with 0.1 M NaOH. After addition of 
Coomassie® Protein Assay reagent (Fluka), the samples were homogeneized and the 
absorbance was quantified at 595 nm in an ELISA plate reader (Synergy HT, Biotek). 
Results were expressed as mg/mL. 
 
2.2.2 TRAP activity quantification 
TRAP activity was assayed by para-nitrophenilphosphate (pNPP) hydrolysis 
method (22,49–52). Cell cultures were washed twice with PBS and solubilized with 0.1% 
(V/V) Triton X-100. Cellular extracts were incubated with 22.5 mM pNPP in 0.225 M 
sodium acetate, 0.3375 M KCl, 0.1% Tx-100, 22.5 mM sodium tartarate and 0,225 mM 
iron chloride (pH = 5.8) for 1 hour at 37ºC. After stopping the reaction with 5 M NaOH, 
the absorbance of the samples was measured at 400 nm in an ELISA plate reader (Synergy 
HT, Biotek). Results were normalized with the corresponding total protein content values, 
and were expressed as nmol/min/μgprotein. 
 
2.2.3 ALP activity quantification 
ALP activity was assayed by pNPP hydrolysis method (52). Cell cultures were 
washed twice with PBS and solubilized with 0.1% (V/V) Triton X-100. Cellular extracts 
were incubated with 22.5 mM pNPP in 0.15 M bicarbonate buffer (pH 10.3) for 1 hour at 
37ºC. After stopping the reaction with 5 M NaOH, the absorbance of the samples was 
measured at 400 nm in an ELISA plate reader (Synergy HT, Biotek). Results were 
normalized with the corresponding total protein content values, and were expressed as 
nmol/min/μgprotein. 
 
 
Effects of antihypertensive drugs in the differentiation and activation of human bone cells 
 
20 
 
 
2.2.4 Cellular proliferation/viability 
 The cellular proliferation/viability assessment was performed by MTT (3-(4, 5- 
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) assay. Cell cultures were 
incubated with 5mg/mL MTT, for 3 hours at 37ºC. After incubation, the culture medium 
was removed and dimethyl sulfoxide (DMSO) was added. The absorbance was quantified 
at 550 nm in an ELISA plate reader (Synergy HT, Biotek). 
 
2.2.5 Histochemical staining of TRAP 
 Cell cultures were fixed with 3.7% formaldehyde for 15 minutes and then washed 
with distilled water. The cells were stained for TRAP with Acid Phosphatase, Leukocyte 
kit (Sigma), according to manufacturer’s instructions. Shortly, after fixation the cells were 
incubated with 0.12 mg/mL naphtol AS-BI, in the presence of 6.76 nM tartrate and 0.14 
mg/mL Fast Garnet GBC, for 1 hour at 37ºC in the dark. Cell layers were washed and 
stained with hematoxilin. After being washed with water, cells were visualized by light 
microscopy. Cells multinucleated and positive for TRAP were counted (Nikon TMS phase 
contrast microscope). 
 
2.2.6 Histochemical staining of ALP 
  Cell cultures were histochemically stained for the activity of ALP. The method 
used was based on the hydrolysis of α-naphtyl phospate by ALP and the precipitation of 
phosphate liberated by reaction with a salt, giving rise to the formation of a coloured 
product. The cell cultures were fixed with 1.5% glutaraldehyde in 0.14 M sodium 
cacodylate buffer for 20 minutes and then washed with cacodylate buffer. Then, samples 
were incubated at 37ºC in the dark for 1 hr in 0.1 M Tris buffer, pH 10 containing 2 mg / 
ml Na-α-naphtyl phospatase and 2 mg / ml of Fast blue RR salt. The reaction was stopped 
by rinsing the samples with distilled water. A positive reaction is identified by the presence 
of a brown to black colour, in accordance with the amount of the enzyme. Cells were 
visualized under a Nikon TMS phase contrast microscope. 
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2.2.7 Histochemical staining for the presence of phosphate deposits 
   Phosphate deposits present in the matrix were identified by the method of von 
Kossa. After fixation with 1.5% glutaraldehyde in 0.14 M sodium cacodylate buffer, the 
cultures were washed with cacodylate buffer and were overlaid with a solution of silver 
nitrate 1% and subjected to UV radiation for 1 h (UV lamp, Vilber Lourmat , VL model 
4L). After washing with distilled water, cells were incubated with a solution of sodium 
thiosulfate 5% for 2 min, and washed again with distilled water. The positive reaction is 
reflected by the appearance of black deposits in the cell layer. Cells were visualized under 
a Nikon TMS phase contrast microscope. 
 
2.2.8 Staining of actin, VNR, CTR and nuclei and visualization by 
confocal laser scanning microscopy (CLSM) 
 Cell cultures were washed twice with PBS and fixed with 3.7% para-formaldehyde 
for 15 minutes. Cells were permeabilized with 0.1% (V/V) Triton X-100 for 5 minutes and 
stained for F-actin with 5 U/mL Alexa Fluor
®
 647-Phalloidin (Invitrogen), for VNR and 
CTR with 50 μg/mL mouse IgGs anti-VNR and IgGs anti-CTR (R&D Systems), 
respectively, and for nuclei with 500 nM propidium iodide, in the case of osteoblasts. Anti-
VNR and anti-CTR detection was performed with 2 μg/mL Alexa Fluor® 488-Goat anti-
mouse IgGs. Cultures were visualized by CLSM (Leica TCP SP2 AOBS confocal 
microscope). 
 
2.2.9  Apoptosis quantification 
Apoptosis was quantified by measuring the caspase-3 activity. For that, cell 
cultures were washed twice with PBS and assessed for caspase-3 activity with the 
EnzCheck® Caspase-3 Assay Kit #2 (Molecular Probes), according to manufacturer’s 
instructions. Fluorescence was analysed at 496/520 nm (excitation/emission) in an ELISA 
plate reader (Synergy HT, Biotek). Results were presented as a % of activity (normalized 
with the corresponding total protein content value), compared to the control. 
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2.2.10  Calcium phosphate resorbing ability  
Control and AHDs-treated osteoclast cell cultures and co-cultures preformed on 
calcium phosphate coated culture plates (BD BioCoat™ Osteologic™ Bone Cell Culture 
Plates, BD Biosciences). After 21 days of culture, cells were bleached with 6% NaOCl and 
5.2% NaCl, and the remaining calcium phosphate layers were visualized by phase contrast 
light microscopy (Nikon TMS phase contrast microscope). Resorption lacunae were 
identified and total resorbed area was quantified with ImageJ 1.41software.  
 
2.2.11  RT-PCR analysis 
Total RNA from cell cultures was extracted and isolated with RNeasy® Mini Kit 
(QIAGEN) according to manufacturer’s instructions. RNA was quantified by measuring 
the absorbance of the samples at 260 nm and by calculating the A260nm/A280 nm ratio, 
respectively. The expression of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and 
COL I by osteoblasts, GAPDH and CATK by PBMC and GAPDH, COL I and CATK by 
co-cultures, was assessed by RT-PCR. RNA, 0.5 mg, was reverse transcribed and 
amplified (25 cycles) with the Titan One Tube RT-PCR System (Roche), with an annealing 
temperature of 55ºC.The primers used are listed on table 1. RT-PCR products were 
electrophoretically separated on a 1% (w/v) agarose gel and gel band intensities were 
quantified with ImageJ 1.41 software. Values were considered as a percentage of the 
corresponding GAPDH value of each experimental condition. 
 
Table 1: Primers used for characterization of cell cultures  
Gene 5’ Primer 3’ Primer 
GADP
H 
5’-CAGGACCAGGTTCACCAACAAGT-3’ 5’-GTGGCAGTGATGGCATGGACTGT-3’ 
CATK 5’-AGGTTCTGCTGCTACCTGTGGTGAG-3’ 5’-CTTGCATCAATGGCCACAGAGACAG-3’ 
COL1 5’-TCCGGCTCCTGCTCCTCTTA-3’ 5’-ACCAGCAGGACCAGCATCTC-3’ 
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2.2.12  Assessment of the intracellular mechanisms involved in the 
osteoclastogenic and the osteoblastogenic cell response 
To evaluate the influence of several signaling pathways, involved in the 
osteoclastogenic and in the osteoblastogenic processes, cell cultures were supplemented 
with different specific inhibitors of signalling pathways, namely: U0126 1 M (methyl 
ethyl ketone (MEK) inhibitor), PDTC 10 M (NFkB inhibitor), GO6983 5 M (protein 
kinase C (PKC) inhibitor) and SP600125 10 M (c-Jun N-terminal kinase (JNK) inhibitor) 
(52). Cell cultures were assessed for total protein content and for TRAP and ALP 
activities. 
 
2.3 Statistical analysis  
 
Data presented in this work are the means of separate experiments performed with 
cells from different blood donors. Three replicas of each condition were made for each 
experiment and data are expressed as the mean ± standard deviation. Data were evaluated 
using a two-way analysis of variance (ANOVA) and no significant differences in the 
pattern of the cell behavior were observed. Statistical differences found between control 
and experimental conditions were determined by Bonferroni’s method. For values of p ≤ 
0.05, differences were considered statistical significant.  
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Results 
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3.1 PBMC 
 
3.1.1 TRAP activity quantification   
 
 
 
 
 
 
 
 
 
 
Figure 3.1: TRAP activity of PBMC cultures maintained in the presence of recombinant 
M-CSF and RANKL and treated with the AHDs. 
 
Figure 3.1 shows the TRAP activity of PBMC cultures maintained in the presence 
of recombinant M-CSF and RANKL, in the absence (control) or supplemented with 
different AHDs, cultured for 7, 14 and 21 days. At control conditions, TRAP activity 
increased until day 14 and stabilized from days 14 to 21. The tested AHDs revealed 
different abilities to modulate osteoclastogenesis. Supplementation with low doses of 
amlodipine and felodipine resulted in a significant increase of TRAP activity. The 
maximum response was achieved with 10
-7
 M, with an increase of about 29% and 35.5% 
for amlodipine and felodipine, respectively. At concentrations higher than 10
-6
 M, both 
molecules elicited a decrease on osteoclastic behavior. Compared to the control, the 
presence of diltiazem, lercanidipine and nifedipine resulted in a dose-dependent decrease 
of TRAP activity, which became statistically significant (16%, 23% and 16%) for 
concentrations higher than 10
-8
, 10
-7
 and 10
-6
 M, respectively. 
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3.1.2 Histochemical staining of TRAP  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. 2: Number of TRAP+ multinucleated cells on PBMC cultures maintained in the 
presence of recombinant M-CSF and RANKL and treated with the AHDs. 
 
Figure 3.2 shows that, after 14 and 21 days of culture, the profile observed for the 
number of TRAP-positive multinucleated cells in PBMC cultures followed a pattern 
similar to that observed in TRAP activity, either in control conditions or in the presence of 
AHDs. Shortly, supplementation with the AHDs resulted in an increase of number of 
TRAP-positive multinucleated cells at low doses, in the case of amlodipine and felodipine 
(25% and 31%, respectively).The presence of the remaining AHDs resulted in a dose-
dependent decrease of number of TRAP-positive multinucleated cells. 
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3.1.3 Staining of actin, VNR, CTR  and visualization by CLSM 
 
 
 
 
 
 
 
 
 
Figure 3.3: Presence of multinucleated cells displaying actin rings and VNR or CTR in 
PBMC cultures assessed by CSLM. Fluorescence images showing actin rings (blue) and 
VNR or CTR (green). White bars represent 120 µm. 
 
 PBMC cultures were stained for actin and for VNR and CTR and visualized by 
CLSM (figure 3.3). It was possible to visualize cells displaying the analyzed osteoclast-
features, which confirmed the presence of osteoclasts in the tested conditions. The amount 
of osteoclastic cells in the different conditions was somehow correlated with the qualitative 
pattern observed for TRAP activity. 
 
 
 
 
 
 
 
 
Control Lercanidipine 10
-7
M 
VNR 
CTR 
Effects of antihypertensive drugs in the differentiation and activation of human bone cells 
 
30 
 
3.1.4 Apoptosis quantification  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 3.4: Caspase-3 activity on PBMC cultures 
 
Supplementation with amlodipine and felodipine revealed a decrease of caspase-3 
activity at concentration 10
-6
 M and an increase of caspase activity at dose 10
-4
 M, 
compared to concentration 10
-8
 M (figure 3.7). The other drugs elicited a dose-dependent 
increase of caspase activity. 
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3.1.5 Calcium phosphate resorbing ability 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: Calcium phosphate resorbing ability and total resorbed area of PBMC cultures 
mantained in the presence of recombinant M-CSF and RANKL and treated with the AHDs.  
 
In figure 3.5, it was observed that the presence of amlodipine and felodipine 
induced an increase of about 28.5% and 43%, respectively, on the total resorbed area. On 
the other hand, the other drugs elicited a decrease on the resorbing activity (about 22%, 
30% and 27% lower than the control, for diltiazem, lercanidipine and nifedipine, 
respectively).  
 
Control (1% DMSO) Amlodipine 10
-7
 M Felodipine 10
-7
 M 
Diltiazem 10
-8
 M Lercanidipine 10
-7
 M Nifedipine 10
-6
 M 
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3.1.6 Assessment of the intracellular mechanisms involved in the 
osteoclastogenic cell response 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: TRAP activity in PBMC cultures exposed to the AHDs and 
treated with specific inhibitors of MEK (U0126), NFkB (PDTC), PKC 
(GO6983) and JNK (SP600125) signaling pathways. 
 
PBMC cultures were treated with specific inhibitors of several signaling pathways 
involved in the osteoclastic differentiation and function; TRAP activity measured at days 
7, 14 and 21 is presented in figure 3.6.  
In control PBMC cultures, NFkB appears to be particularly important, as the 
presence of PDTC practically abolished the production of TRAP. U0126, GO6983 and 
SP600125 induced a partial decrease in the production of TRAP. In general, the presence 
of the AHDs caused some significant changes in the described behavior. A higher 
inhibition in TRAP activity than the one achieved in the control was seen in the presence 
of U0126, in cell cultures treated with amlodipine, felodipine and diltiazem. In the 
presence of PDTC, it was observed a lower inhibition in TRAP activity, compared to the 
control, especially with felodipine and diltiazem. The presence of GO6983 did not affect 
the cellular response in cell cultures treated with felodipine and diltiazem, while in the 
presence of the remaining AHDs it elicited a decrease on TRAP activity higher than the 
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one observed in the control. Osteoclastic behavior of cell cultures supplemented with 
diltiazem and nifedipine were not significantly affected by SP600125. On the other hand, 
the presence of this molecule caused a sharp decrease on TRAP cellular response on 
PBMC cultures performed in the presence of amlodipine, felodipine and lercanidipine. 
 
3.2 Osteoblasts 
 
3.2.1 Cellular proliferation/viability 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7: Cell proliferation/viability of osteoblasts, evaluated by the MTT assay. 
 
In figure 3.7, it is observed that osteoblast cultures displayed an increase on cell 
proliferation/viability through the 21 days of culture. The presence of AHDs at low doses 
didn’t alter significantly that behavior, except in the case of diltiazem, which elicited a 
stimulation of cellular proliferation/viability. The maximum response was achieved at 10
-7
 
M, with an increase of about 65% for diltiazem compared to the control. At high doses, all 
AHDs cause a decrease on cell proliferation/viability. 
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3.2.2 ALP activity quantification   
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8: ALP activity of osteoblasts treated with the AHDs. 
 
Figure 3.8 demonstrates the ALP activity of osteoblasts maintained in the absence 
(control) or presence of different AHDs, cultured for 7, 14 and 21 days. In the control, 
ALP activity increased mostly until day 14 and tended to stabilize afterwards. The tested 
AHDs revealed diverse abilities to modulate osteoblastogenesis. At low doses, diltiazem 
and lercanidipine caused an increase on ALP activity. At concentrations higher than 10
-6
 
M, both molecules elicited a decrease on osteoblastic behavior. The highest response was 
achieved with 10
-7
 M, with an increase of about 24% and 16% for diltiazem and 
lercanidipine, respectively. Compared to the control, the presence of amlodipine, 
felodipine and nifedipine resulted in a dose-dependent decrease of ALP activity, which 
became statistically significant (19%, 5% and 16%) for concentrations higher than 10
-7
, 10
-
7
 and 10
-6
 M, respectively. 
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3.2.3 Staining of actin and nuclei and visualization by CLSM 
 
 
 
 
 
 
Figure 3.9: Presence of multinucleated cells displaying actin rings and nuclei in osteoblasts 
cultures assessed by CSLM. Fluorescence images showing actin rings (gree) and nuclei 
(red). White bars represent 120 µm. 
 
Osteoblasts cultures were stained for actin and nuclei and visualized by CLSM 
(figure 3.9), which confirmed the presence of osteoblasts in tested conditions. The cells 
were spread over the bottom of the culture wells and exhibited a proper elongated 
morphology. The amount of osteoblastic cells in the different conditions was somehow 
correlated with the qualitative pattern observed for ALP activity. 
 
 
 
 
 
 
 
 
 
 
 
   Control Diltiazem 10
-7
M 
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3.2.4 Apoptosis quantification  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10: Caspase-3 activity on osteoblasts cultures 
 
Figure 3.10 demonstrates that amlodipine and lercanidipine did not affect 
significantly caspase-3 activity at 10
-8
 M and 10
-6
 M, while at 10
-4
 M it induced an increase 
on cell response. Felodipine and nifedipine elicited a higher apoptotic behavior at high 
doses. Supplementation with diltiazem revealed a decreased in caspase activity at 
concentration 10
-6
 M. 
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3.2.5 Histochemical staining of ALP 
 
 
 
 
 
 
Figure 3.11: Histochemical staining of ALP in osteoblasts cultures. 
 
The osteoblasts cultures showed positive staining reaction in the presence of ALP 
(figure 3.11). The AHDs treated cultures had a relatively uniform staining, being evidence 
for areas of high intensity of staining associated with cell groups. 
 
 
 
 
 
 
 
 
 
 
 
Control Amlodipine        Felodipine 
Diltiazem          Lercanidipine       Nifedipine 
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3.2.6 RT-PCR analysis 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12: Expression of osteoblastic-associated genes, and representative agarose gel. 
Densitometric analysis of the RT-PCR products, normalized by GAPDH, of osteoblasts 
cultures.  1 – control; 2 – amlodipine; 3 – felodipine; 4 – diltiazem; 5 – lercanidipine; 6 – 
nifedipine. 
 
Cell layer was assessed by RT-PCR (figure 3.12), in order to verify the expression 
of the housekeeping gene GAPDH and the osteoblastic gene COL1. The osteoblasts 
cultures revealed expression of both genes, in the presence of AHDs. In the control, the 
expression of COL1 was low, and was not significantly affected by the presence of 
amlodipine, felodipine and nifedipine. However, when cell cultures were treated with 
diltiazem and lercanidipine, the expression levels increased significantly about 7x and 9x, 
respectively. 
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3.2.7 Assessment of the intracellular mechanisms involved in the 
osteoblastogenic cell response 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13: ALP activity in osteoblasts cultures exposed to the 
AHDs and treated with specific inhibitors of MEK, NFkB, PKC and 
JNK signaling pathways. 
 
Osteoblasts cultures were treated with specific inhibitors of several signaling 
pathways involved in the osteoblastic differentiation and function; ALP activity was 
quantified and the results are presented in figure 3.13. In control conditions (absence of the 
AHDs), the presence of all inhibitors caused a decrease in the levels of this enzyme.  
Comparatively, the presence of the AHDs showed some significant differences. A higher 
inhibition in ALP activity was seen in the presence of U0126, when cell cultures were 
treated with amlodipine and nifedipine. Diltiazem and felodipine-supplemented cell 
cultures revealed a similar inhibition than the one observed in the absence of any AHDs, 
while in the presence of lercanidipine U0126 did not significantly affect ALP activity. 
PDTC caused a lower inhibition in the presence of the AHDs, although with the exception 
of amlodipine, whose inhibition was higher than in the control. The presence of GO6983 
caused a significant decrease in ALP activity in the presence of all drugs. SP600125 
elicited a lower inhibition on cell response in the presence of amlodipine, lercanidipine and 
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nifedipine, while in the presence of the remaining two AHDs (felodipine and diltiazem), 
the inhibition was similar to the one observed in the control.  
 
3.3 Co-cultures of PBMC and osteoblasts  
 
3.3.1 TRAP activity quantification   
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14: TRAP activity of co-cultures treated with the AHDs. 
 
Figure 3.14 demonstrates the TRAP activity of co-cultures, in the absence (control) 
or supplemented with different AHDs, cultured for 7, 14 and 21 days. TRAP activity 
increased until day 14 and stabilized after that, at control conditions. Supplementation with 
low doses of amlodipine and felodipine resulted in a significant increase of TRAP activity. 
The maximum response was achieved with 10
-7
 M, with an increase of about 29% and 40% 
for amlodipine and felodipine, respectively. At concentrations higher than 10
-5
 M, both 
molecules elicited a decrease on osteoclastic behavior. Compared to the control, the 
presence of diltiazem, lercanidipine and nifedipine resulted in a dose-dependent decrease 
of TRAP activity, which became statistically significant (24%, 25% and 34%) for 
concentrations higher than 10
-7
, 10
-7
 and 10
-6
 M, respectively. 
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3.3.2 Histochemical staining of TRAP  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15: Number of TRAP+ multinucleated cells on co-cultures treated with the AHDs. 
 
Figure 3.15 shows that, after 14 and 21 days of culture, the profile observed for the 
number of TRAP-positive multinucleated cells in co-cultures followed a pattern similar to 
that observed in TRAP activity, either in control conditions or in the presence of AHDs. 
Shortly, supplementation with the AHDs resulted in an increase of number of TRAP-
positive multinucleated cells at low doses, in the case of amlodipine and felodipine (33% 
and 41.5%, respectively). The presence of the remaining AHDs resulted in a dose-
dependent decrease of number of TRAP-positive multinucleated cells. 
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3.3.3 Assessment of the intracellular mechanisms involved in the 
osteoclastogenic cell response 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16: TRAP activity in co-cultures exposed to the AHDs and 
treated with specific inhibitors of MEK, NFkB, PKC and JNK 
signaling pathways. 
 
Co-cultures were treated with specific inhibitors of several signaling pathways 
involved in osteoclastic differentiation and function; TRAP activity measured in this 
culture is presented in figure 3.16. In control co-cultures, all signaling pathway inhibitors 
induced a decrease in TRAP activity, especially PDTC, which caused an almost total 
decrease. The one exception was U0126, which did not affect significantly cell behavior. 
In general, the presence of the AHDs showed some significant alterations on this pattern. 
Compared to the control, an inhibition in TRAP activity was seen in the presence of 
U0126. Supplementation with PDTC elicited a similar response in co-cultures treated with 
all the tested AHDs, although less pronounced in the case of nifedipine. The presence of 
GO6983 caused a higher inhibition on TRAP activity in the presence of amlodipine, while 
co-cultures treated with felodipine, lercanidipine and nifedipine were less affected by that 
molecule. SP600125 caused a lower inhibition in the presence of diltiazem and nifedipine, 
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while in the presence of the remaining AHDs, its inhibition profile was similar to the 
control.  
 
3.3.4 ALP activity quantification   
 
 
 
 
 
 
 
 
 
 
 
Figure 3.17: ALP activity of co-cultures treated with the AHDs. 
 
Figure 3.17 demonstrates the ALP activity of co-cultures maintained in the absence 
(control) or presence of different AHDs, cultured for 7, 14 and 21 days. In control, ALP 
activity increased mostly until day 14 and tended to stabilize afterwards. At low doses, 
amlodipine, felodipine and diltiazem caused an increase on ALP activity compared to the 
control. The maximum response was achieved with 10
-7
 M, with an increase of about 20%, 
46% and 16% for amlodipine, felodipine and diltiazem, respectively. At concentrations 
higher than 10
-5
 M, these molecules elicited a decrease on osteoblastic behavior. Compared 
to the control, the presence of lercanidipine and nifedipine resulted in a dose-dependent 
decrease of ALP activity, which became statistically significant (23% and 21%) for 
concentrations higher than 10
-7
 and 10
-6
 M, respectively. 
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3.3.5 Assessment of the intracellular mechanisms involved in the 
osteoblastogenic cell response 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.18: ALP activity in co-cultures exposed to the AHDs and 
treated with specific inhibitors of MEK, NFkB, PKC and JNK 
signaling pathways. 
 
Co-cultures were treated with specific inhibitors of several signaling pathways 
involved in osteoblastic differentiation and function; ALP activity measured in this culture 
is presented in figure 3.18. In the control, all the tested inhibitors caused a decrease in the 
production of ALP. Comparatively, the presence of the AHDs elicited some important 
changes. Osteoblastic behavior of cell cultures supplemented with felodipine was not 
significantly affected by U0126. Supplementation with lercanidipine and nifedipine caused 
a lower inhibition on ALP activity, while in the presence of the remaining two AHDs the 
response was identical to the control. PDTC appeared to have a lower inhibitory ability in 
the presence of the AHDs, particularly in the case of diltiazem, where it did not affect cell 
response.  GO6983 showed a partial inhibitory profile in all tested conditions, except in the 
case of co-cultures treated with felodipine. SP600125 caused an inhibition (similar to the 
control) on ALP activity in co-cultures treated with amlodipine, felodipine and diltiazem. 
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On the other hand, in the presence of lercanidipine and especially nifedipine, that inhibitor 
had little or no effect on osteoblastic behavior of co-cultures.  
 
3.3.6 Staining of actin, VNR, CTR  and visualization by CLSM 
 
 
 
 
 
 
 
 
 
Figure 3.19: Presence of multinucleated cells displaying actin rings and VNR or CTR in 
co-cultures assessed by CSLM. Fluorescence images showing actin rings (blue) and VNR 
or CTR (green). White bars represent 120 µm. 
 
Figure 3.19 shows representative images of co-cultures stained for actin and for 
VNR and CTR and visualized by CLSM. It was possible to visualize cells displaying the 
analyzed osteoclast-features, which confirms the presence of osteoclasts and osteoblasts in 
tested conditions. The amount of osteoclastic cells in the different conditions was 
somehow correlated with the qualitative pattern observed for TRAP. Due to the low 
amount of osteoblastic cells used in the co-cultures, comparatively to the PBMC amount, 
osteoblastic cells were not able to be observed by CLSM. 
 
 
 
Control Felodipine 10
-7
M 
VNR 
CTR 
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3.3.7 Calcium phosphate resorbing ability 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.20: Calcium phosphate resorbing ability and total resorbed area of co-cultures 
treated with the AHDs. 
 
In figure 3.20, it was observed that the presence of amlodipine and felodipine 
induced a significant increase on the resorbed area on co-cultures (about 69% and 84% 
higher than the control for amlodipine and felodipine, respectively). In contrast, the other 
drugs elicited a decrease on the resorbing activity (about 24%, 23% and 38% lower than 
the control for diltiazem, lercanidipine and nifedipine, respectively).  
 
Control (1% DMSO)     Amlodipine 10
-7
 M      Felodipine 10
-7
 M 
Diltiazem 10
-7
 M    Lercanidipine 10
-7
 M     Nifedipine 10
-6
 M 
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3.3.8 Histochemical staining of ALP 
 
 
 
 
 
 
 
Figure 3.21: Histochemical staining of ALP in co-cultures. 
 
The co-cultures showed positive staining reaction in the presence of ALP (figure 
3.21). The AHDs treated cultures had a relatively uniform staining, being evidence for 
isolated cells and not for areas associated with cell groups. 
 
 
 
 
 
 
 
 
 
 
Control           Amlodipine           Felodipine 
              Diltiazem         Lercanidipine           Nifedipine 
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3.3.9 RT-PCR analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.22: Expression of osteoclastic and osteoblastic-associated genes, and 
representative agarose gel. Densitometric analysis of the RT-PCR products, normalized by 
GAPDH, of co- cultures.  1 – control; 2 – amlodipine; 3 – felodipine; 4 – diltiazem; 5 – 
lercanidipine; 6 – nifedipine. 
 
Co-cultures layers were assessed by RT-PCR (figure 3.22), in order to verify the 
expression of GAPDH, the osteoclastic gene CATK and the osteoblastic gene COL1.  
The co-cultures revealed expression of the analyzed osteoclastic gene, in the control 
and in the presence of AHDs. When co-cultures were treated with nifedipine, the 
expression levels increased about 26%. With the supplementation with amlodipine, 
felodipine and lercanidipine the expression levels of the analyzed gene were not 
significantly affected, while in the presence of diltiazem the value increase about 37%. 
The osteoblastic gene analyzed was expressed at very low levels, as revealed by the 
agarose gel. However, in the densitometric analysis it was possible to determine its 
expression. When co-cultures were treated with amlodpine, felodipine and diltiazem the 
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expression levels increased about 148%, 173% and 92%, respectively. With the 
supplementation with lercanidipine and nifedipine the expression levels of analyzed gene 
decreased about 57% and 33%, respectively. 
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CHAPTER IV 
 
Discussion 
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In the bone microenvironment, the mutual osteoclast-osteoblast communication has 
a central role in their differentiation and function. The parallel coordinated bone resorption 
and formation events are highly complex and regulated processes, responsible for the life-
long bone remodeling with the aim of ensure a healthy tissue formation and maintenance 
(52).  AHDs can have an indirect impact on osteoporosis as well as direct effects on bone 
metabolism, strength, and density. Calcium has a central role in bone strength and in the 
balance between osteoblastic and osteoclastic activities, the basis of the bone remodeling 
process (46). The present study examined the effects of amlodipine, felodipine, diltiazem, 
lercanidipine and nifedipine on human osteoclasts and osteoblasts differentiation and 
activation in three different cell culture models: PBMC, osteoblasts and co-cultures of 
osteoblasts and osteoclasts. 
The effects of AHDs on the osteoclast and osteoblast development are scarcely 
reported in the literature, with only a few published studies about it. Moreover, these 
studies have just analysed the effect of two AHDs – amlodipine and nifedipine on bone 
cells. One experiment was performed on outbred rats and it was observed that amlodipine 
treatment may induce deceleration of bone metabolism. The expression of BMP-2 in 
proximal tibia was investigated by means of immunoblotting, and bone mineral density 
was measured by Dual-energy X-ray Absorptiometry in lumbar and caudal vertebrae and 
in femoral areas. The results showed induced suppression of bone turnover, in particular by 
decreasing osteoformation, and to a lesser extent osteoresorption (13). Other study 
investigated the effects of different amlodipine and lacidipine doses on ovariectomized rat 
femurs' calcium and phosphor content. Bone calcium and phosphate concentrations were 
measured by a Wavelength Dispersive Spectrometer. The findings suggested that 
amlodipine decreased the bone loss, having a beneficial effect on bone metabolism (14). 
Another work using osteoblastic MC3T3-E1 cells revealed that nifedipine and amlodipine 
weakly block calcium channels on osteoblastic cells, and also partially elevated ALP 
activity at higher concentrations, by the quantification of ALP activity, DNA and 
hydroxyproline content, mineralization and cytosolic calcium measurement (6). In a study 
conducted with 11 men given nifedipine for three years, no differences in bone mass and 
bone turnover markers were found as compared to the control group (7). Another study 
showed decreased plasma calcitonin levels in postmenopausal women treated with 
nifedipine (7). Finally, the effects of amlodipine were assessed in an 8-week study, which 
revealed no changes in bone remodeling markers of menopausal women (7). Taken 
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together, the published studies were performed in different experimental models, of 
different origins and mainly in vivo models, which can help to explain the contradictions 
found among the data obtained.  Moreover, in order to have a more accurate perspective of 
the effects of calcium channel blockers on human bone metabolism, it is of the utmost 
importance to assess the way human bone cells behave in the presence of those molecules. 
Up till now there is no data regarding this issue. Nevertheless, it is important to note that 
this represents only the first step towards a physiological understanding of how AHDs may 
affect bone tissue, and a correlation to the clinical situation can not be directly predicted, 
due to the complex in vivo environment.  
PBMC cultures were performed in the presence of the osteoclastogenic 
recombinant growth factors M-CSF and RANKL. Several studies have shown that both M-
CSF and RANKL are required for the expression of typical osteoclastic genes, including 
TRAP, CTR, VNR and CATK (35). TRAP activity is observed as an important 
cytochemical marker of osteoclasts; its concentration is utilized as a biochemical marker of 
osteoclast function and, consequently, as an indicator of bone resorption (53). It was 
observed that the tested AHDs had the ability to differentially affect osteoclastogenesis. At 
low doses, amlodipine and felodipine caused an increase on osteoclastic differentiation, 
while the other drugs inhibited it, as observed by TRAP activity, quantification of TRAP+ 
multinucleated cells, calcium phosphate resorbing ability and expression of CATK gene. 
At higher doses, all the molecules caused a decrease on the process, which is in agreement 
with the results obtained previously by other authors (6,13,14). The observed results were 
at least partially accompanied by a corresponding change on apoptosis rate, determined by 
caspase-3 activity.  
PBMC cultures were also analyzed for the involvement of several signaling 
pathways, with a well-established role in osteoclastogenesis (52). In general, the presence 
of the AHDs caused some significant alterations in the relative contribution of the tested 
pathways on the response of osteoclastic cells. Concerning the intracellular signalling 
pathways, MEK pathway was not significantly affected by nifedipine; lercanidipine caused 
a lower influence of the pathway, while it was upregulated by the remaining AHDs. NFkB 
pathway appeared as a major osteoclastogenic intracellular mechanism, although in the 
presence of felodipine and diltiazem it seemed to lose some of its relevance. PKC signaling 
pathway did not contribute to the cellular response in PBMC cultures treated with 
felodipine and diltiazem, but in the presence of the other AHDs it was obtained a decrease 
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on TRAP activity higher than the one observed in the control. This reveals the importance 
of this pathway in the osteoclast differentiation, especially in the presence of nifedipine, 
where it practically abolished osteoclast differentiation. JNK pathway was not affected by 
diltiazem and nifedipine, while the remaining AHDs caused a higher involvement of that 
pathway on osteoclastic response. 
Osteoblasts  play  a  crucial  role  in  bone  formation  through  their  
proliferation, differentiation and bone tissue formation.  ALP is a membrane bound 
enzyme that is often used as a marker for osteogenic differentiation,  a  complex  process  
of  sequential expression  of early and late marker  proteins (35,37). MTT assay was used 
to determine the viability/proliferation of the cells. Cell viability can be defined as the 
number of healthy cells in a sample. Cell viability assays are often useful when primary 
cells are isolated and maintained in culture to determine optimal culture conditions for 
these populations. Cell proliferation is the determination of the number of dividing cells 
(54).  It was observed that the tested AHDs had the ability to differentially affect not only 
cell viability/proliferation but also osteoblastogenesis. At low doses, diltiazem and 
lercanidipine caused an increase on osteoblastic differentiation, which is compatible with 
the results obtained in previously studies (6), while the other drugs inhibited it. At higher 
doses, all the molecules caused a decrease on the process, which can be partly attributed to 
changes in the apoptotic process in the different experimental conditions, which is in line 
with results obtained previously (13).  
Regarding the intracellular signalling pathways, MEK pathway had a contribution 
in the osteoblastogenic response. Cultures treated with lercanidipine were not significantly 
affected by the MEK inhibitor, which suggests that in these conditions MEK pathway may 
not be as important for osteoblastogenesis as it happens in the control. The treatment with 
felodipine and diltiazem had a similar inhibitory profile compared to the control. However, 
ALP activity was marked inhibited in the cultures exposed to the others AHDs, suggesting 
that these molecules might lead to an upregulation of the pathway. NFkB appeared to be 
not so involved in osteoblastogenesis, in the presence of AHDs, except in the case of 
amlodipine, where the observed inhibition was higher than in the control. PKC signaling 
pathway appeared to affect the cellular response in osteoblasts cultures treated with all 
drugs, especially in the presence of felodipine, diltiazem and lercanidipine, where its 
involvement was higher than in the control. JNK pathway appeared to be downregulated 
by amlodipine, lercanidipine and nifedipine and not affected by the remaining two AHDs. 
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In co-cultures, osteoclastic response was stimulated by amlodipine and felodipine at 
low doses. At high doses all AHDs caused a decrease in osteclastogenesis. Co-cultures also 
showed a high osteoblastic response at low doses of amlodipine, felodipine and diltiazem. 
At high doses all drugs revealed a decrease in the differentiation of osteoblasts.  
Co-cultures were also analyzed for the involvement of several signaling pathways, 
with a role in osteoclastogenesis and osteoblastogenesis. The presence of the AHDs 
induced some alterations in the relative contribution of the tested pathways in the response 
of co-cultured osteoclastic and osteoblastic cells. Regarding the osteoclastic response, 
MEK pathway seemed to be upregulated by the tested AHDs. NFkB appeared to be a 
major intracellular mechanism in all the experimental conditions, although with a lower 
relevance in the presence of nifedipine. PKC signaling pathway seemed to be not involved 
in osteoclastogenesis in the presence of felodipine and lercanidipine, while amlodipine 
appeared to upregulate it. In the presence of the remaining AHDs, the involvement of this 
pathway was similar to the control. JNK pathway was negatively affected by diltiazem and 
nifedipine, while the other AHDs caused a similar inhibition profile of osteoclastogenesis, 
compared to the control.  
In relation to the intracellular signalling pathways involving osteoblasts, it was 
observed that in the control the tested inhibitors caused a decrease in ALP activity, which 
indicates that all signaling pathways influence osteoblastic differentiation. Cultures treated 
with felodipine were not significantly affected by U0126, which suggests that in these 
conditions MEK pathway may not be important for osteoblastogenesis. Also, nifedipine- 
and lercanidipine-treated co-cultures revealed a lower inhibition and in the presence of the 
other two AHDs the response was similar to the control. NFkB appears to be not so 
important in cell cultures treated with the AHDs, because the inhibition of osteoblasts 
differentiation is lower than the observed in the control, particularly in the case of 
diltiazem, where it was not observed any inhibition. PKC signaling pathway appears to 
have a partial contribution in all tested conditions, except in the case of co-cultures 
supplemented with felodipine. JNK pathway appears not to be an important pathway with 
supplementation with lercanidipine and nifedipine, because the inhibitor had no effect on 
osteoblasts differentiation. With the remaining drugs a similar inhibition compared to the 
control was observed.  
Taken together, AHDs seemed to cause a direct effect on human osteoclastic and 
osteoblastic differentiation. Interestingly, some of the tested molecules increased while 
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others inhibited the processes in a dose-dependent profile. Furthermore, the osteoclastic 
and osteoblastic response was different when cells were cultured isolated or co-cultured, 
which suggests that AHDs might also modulate osteoclastogenesis and osteoblastogenesis 
in an indirect way, that is, by modulating the osteoclastogenic and osteoblastogenic 
properties of osteoblasts and osteoclasts, respectively. Unraveling the mechanisms beneath 
these observations might help to explain the adverse effects on bone tissue described for 
this drug class.  
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Conclusion 
 
Owing to the high incidence of hypertension and the worldwide high frequency of 
use of AHDs, in particular the calcium channel blockers, it is necessary to study their 
influence on bone metabolism. Since bone diseases are very common –fractures are a 
problem particularly relevant in the elderly –, and given the incidence of hypertension, a 
detailed knowledge of the association of the two factors is crucial in order to act on the 
improvement of the quality of life of patients and their health status in general.  
Comparing plasma Cmax and the obtained results, in the osteoclasts cultures, 
amlodipine and felodipine caused an increase, while diltiazem caused a decrease in TRAP 
activity. Lercanidipine and nifedipine had no effect in its activity. In the osteoblasts 
cultures, diltiazem induced ALP activity, and the others AHDs had no effect in this 
activity. In co-cultures, TRAP activity decreased in the presence of diltiazem and 
nifedipine and was not affected in the presence of the remaining AHDs. ALP activity was 
increased with diltiazem and not affected with the others AHDs.  
The objectives proposed for this study were fulfilled. The effects of AHDs calcium 
channel blockers in human bone cells were studied, on a first stage, by the focus on the 
influence of a wide range of concentrations of five different AHDs in the osteoclastogenic 
and osteoblastogenic process. AHDs caused differential in the osteoclastic and the 
osteoblastic behavior of PBMC, osteoblasts and co-cultures of human PBMC and 
osteoblasts. In order to have some insights on the underlying mechanisms of action of 
AHDs in the cell culture systems used, the influence of several signaling pathways on the 
observed cellular responses was assessed.  
In summary, this work provides new insights on the in vitro effects of AHDs on 
human bone cells, open the doors towards a better understanding about this up till now 
poorly clarified issue. 
 
  
Effects of antihypertensive drugs in the differentiation and activation of human bone cells 
 
60 
 
References  
 
1.  Robling AG, Castillo AB, Turner CH. Biomechanical and Molecular Regulation of Bone 
Remodeling. Annu. Rev. Biomed. Eng. 2006;8:455–98.  
2.  Proff P, Römer P. The molecular mechanism behind bone remodelling: a review. Clin Oral Invest. 
2009;13:355–62.  
3.  Salgado J, Coutinho OP, Reis RL. Bone Tissue Engineering: State of the Art and Future Trends. 
Macromol Biosci. 2004;4:743–65.  
4.  Hill PA. Bone Remodelling. British Journal of Orthodontics. 1998;25:101–7.  
5.  Datta HK, Ng WF, Walker JA, Tuck SP, Varanasi SS. The cell biology of bone metabolism. Journal 
of Clinical Pathology. 2008;61:577–87.  
6.  Ishiya YN, Ugimoto SS. Effects of Various Antihypertensive Drugs on the Function of Osteoblast. 
Biol. Pharm. Bull. 2001;24(6):628–33.  
7.  Pérez-castrillon JL, Justo I, Sanz-cantalapiedra A, Pueyo C, Dueñas A. Effect of the 
Antihypertensive Treatment on the Bone Mineral Density and Osteoporotic Fracture. Current 
Hypertension Reviews. 2005;1:61–6.  
8.  Rejnmark L. Cardiovascular Drugs and Bone. Current Drug Safety. 2008;3:178–84.  
9.  Reyes-García R, Rozas-Moreno P, Muñoz-Torres M. Cardiovascular disease and bone metabolism. 
Endocrinol Nutr. 2011;58:353–9.  
10.  Obradovic N, Vujasinovic N. The Relationship Among Hypertension, Antihypertensive Medications, 
and Osteoporosis: A Narrative Review. Calcif Tissue Int. 2012;  
11.  Ott SM, LaCroix AZ, Scholes D, Ichikawa LE, Wu K. Effects of three years of low-dose thiazides on 
mineral metabolism in healthy elderly persons. Osteoporos Int. 2008;86:1315–22.  
12.  Dvorak MM, Joussineau C De, Carter DH, Pisitkun T, Knepper MA, Gamba G, Kemp PJ, Riccardi 
D. Thiazide Diuretics Directly Induce Osteoblast Differentiation and Mineralized Nodule Formation 
by Interacting with a Sodium Chloride Co-Transporter in Bone. J Am Soc of Nephrol. 
2007;18:2509–16.  
13.  Gradošová I, Živná H, Švejkovská K, Palička V, Tichý A, Živný P. Effects of amlodipine on bone 
metabolism in male albino Wistar rats. Acta Vet. Brno. 2011;80:391–6.  
14.  Halici Z, Borekci B, Ozdemir Y, Cadirci E, Suleyman H. Protective effects of amlodipine and 
lacidipine on ovariectomy-induced bone loss in rats. EJP. 2008;579:241 – 245.  
15.  Shimizu H, Nakagami H, Osako MK, Hanayama R, Kunugiza Y, Kizawa T, Tomita T, Yoshikawa 
H, Ogihara T, Morishita R, Ii A. Angiotensin II accelerates osteoporosis by activating osteoclasts. 
The FASEB Journal. 2008;22:2465–75.  
16.  Lamparter S, Kling L, Schrader M, Ziegler R, Pfeilschifter J. Effects of Angiotensin II on Bone Cells 
In Vitro. Journal of Cellular Physiology. 1998;98(September 1997):89–98.  
17.  Rejnmark L, Vestergaard P, Mosekilde L. Treatment with beta-blockers, ACE inhibitors, and 
calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study. 
J Hypertens. 2006;24:581–9.  
18.  Schlienger RG, Kraenzlin ME, Jick SS, Meier CR. Use of Beta -Blockers and Risk of Fractures. 
JAMA. 2004;292(11).  
19.  Shih TT, Chang C, Tseng WI, Shen L, Liu T. Effect of Calcium Channel Blockers on Vertebral Bone 
Marrow Perfusion of the Lumbar Spine. Radiology. 2004;231(2):24–30.  
20.  Arnett T. Bone structure and Bone remodeling. 44(0):1–10.  
21.  Kneser U, Schaefer DJ, Polykandriotis E, Horch RE. Tissue engineering of bone: the reconstructive 
surgeon’s point of view. J Cell Mol Med. 2006;10:7–19.  
Effects of antihypertensive drugs in the differentiation and activation of human bone cells 
 
61 
 
22.  Rocha MI. Nicotine effects on bone metabolism: in vitro studies with human osteoclasts and co-
cultures of osteoclasts and osteoblasts in an hydroxyapatite surface. Dissertação Mestrado 
Engenharia Biomédica - FEUP. FEUP; 2011.  
23.  Caetano-lopes J, Canhão H, Fonseca JE. Osteoblasts and Bone formation. Acta Reumatologia 
Portuguesa. 2007;32:103–10.  
24.  Zuo C, Huang Y, Bajis R, Sahih M, Li Y. Osteoblastogenesis regulation signals in bone remodeling. 
Osteoporos Int. 2012;23:1653–63.  
25.  Neve A, Corrado A, Cantatore FP. Osteoblast physiology in normal and pathological conditions. Cell 
and Tissue Research. 2011;343:289–302.  
26.  Blair H, Robinson L, Huang C, Sun L, Friedman P, Schlesinger PH, Zaidi M. Calcium and bone 
disease. Biofactors. 2011;37(3):159–67.  
27.  Ginani F, Barboza C. Influence of vitamin D on osteoclastic activity in a bone organ culture model. J 
Bras Patol Med Lab. 2011;619–23.  
28.  Proteins BM, Suda T, Pathology O. Regulation of Osteoblast Differentiation Mediated by Bone 
Morphogenetic Proteins, Hedgehogs, and Cbfa1. Endocrine Reviews. 2000;21(4):393–411.  
29.  Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentation and activation. Nature. 
2003;423(May):337–42.  
30.  Väänänen HK, Zhao H, Mulari M, Halleen JM. The cell biology of osteoclast function. Journal of 
Cell Science. 2000;381:377–81.  
31.  Athanasou NA. The osteoclast - what ’ s new ? Skeletal Radiology. 2011;6:1137–40.  
32.  Roodman GD. Cell biology of the osteoclast. Experimental Hematology. 1999;27:1229–41.  
33.  Väänänen HK, Laitala-leinonen T. Osteoclast lineage and function. Archives of Biochemistry and 
Biophysics. 2008;473:132–8.  
34.  Zhou Y, Lewis TL, Robinson LJ, Brundage KM, Schafer R, Martin KH, Blair H, Soboloff J, Barnett 
JB. The Role of Calcium Release Activated Calcium Channels in Osteoclast Differentiation. J Cell 
Physiol. 2010;(September):1082–9.  
35.  Abu-Amer Y. Advances in Osteoclast Differentiation and Function. Immune, Endocrine & Metabolic 
Disorders. 2005;5:347–55.  
36.  Rodrigues JC, Teixeira CA, Sampaio P, Fernandes MH. Characterisation of the Osteoclastogenic 
Potential of Human Osteoblastic and Fibroblastic Conditioned Media. Journal of Cellular 
Biochemistry. 2010;216:205–16.  
37.  Vaananen HK, Liu Y, Lehenkari P, Uemara T. How do osteoclasts resorb bone? Materials Science 
and Engineering C. 1998;6:205–9.  
38.  Boyce BF, Xing L. Functions of RANKL / RANK / OPG in bone modeling and remodeling. 
Archives of Biochemistry and Biophysics. 2008;473:139–46.  
39.  Ministério da Saúde. Portal da Saúde [Internet]. [cited 2012 Jun 9]. Available from: http://www.min-
saude.pt/portal/conteudos/enciclopedia+da+saude/doencas/doencas+do+aparelho+circulatorio/hiperte
nsao+arterial.htm 
40.  Fundação Portuguesa de Cardiologia [Internet]. [cited 2012 Jun 9]. Available from: 
http://www.fpcardiologia.pt/detalhesNoticia.aspx?id=171 
41.  Cortez-Dias N, Martins S, Belo A, Fiuza M. Prevalência e Padrões de tratamento da Hipertensão 
arterial nos Cuidados de Saúde Primários em Portugal. Resultados do Estudo VALSIM. Rev Port 
Cardiol. 2009;499–523.  
42.  Infarmed. Prontuário Terapêutico [Internet]. [cited 2012 Jun 9]. Available from: 
http://www.infarmed.pt/formulario/navegacao.php?paiid=76 
43.  Whyte I, Buckely N, Dawson A. Calcium channel blockers. Medicine [Internet]. Elsevier Ltd; 
2011;40(3):112–4. Available from: http://dx.doi.org/10.1016/j.mpmed.2011.12.022 
44.  Yousef WM, Omar AH, Morsy MD, El-wahed MMA, M N. The mechanism of action of calcium 
channel blockers in the treatment of diabetic nephropathy. Diabetes & Metabolism. 2005;13:76–82.  
Effects of antihypertensive drugs in the differentiation and activation of human bone cells 
 
62 
 
45.  Cappuccio FP, Meilahn E, Zmuda JM, Cauley JA, Fractures O. High blood pressure and bone-
mineral loss in elderly white women : a prospective study. The Lancet. 1999;354:971–5.  
46.  Metz JA, Morris CD, Roberts LA, Mcclung MR, Mccarron DA. Blood pressure and calcium intake 
are related to bone density in adult males. British Journal of Nutrition. 1999;383–8.  
47.  Vestergaard P, Rejnmark L, Mosekilde L. Hypertension is a risk factor for fractures. Calcif Tissue 
Int. 2009;84:103–11.  
48.  Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein 
utilizing the principle of protein-dye binding. Anal. Biochem. 1976;72:248–54.  
49.  Rodrigues JC, Moniz KA, Teixeira MR, Fernandes MH. Variability of the Paracrine-Induced 
Oteoclastogenesis by Human Breast Cancer Cell Lines. Journal of Cellular Biochemistry. 
2012;1079(November 2011):1069–79.  
50.  Fernandes A da S. Development and characterization of a co-culture system of human osteoclastic 
and osteoblastic cells and application on a biocompatibility study. Faculdade de Ciências da 
Universidade do Porto. FCUP; 2009.  
51.  Costa-Rodrigues J, Martins EG, Fernandes MH. Induced osteoclastogenesis by fluoroquinolones in 
unstimulated and stimulated human osteoclast precursor cells. Bone. 2012;51:17–27.  
52.  Rodrigues C, Costa-Rodrigues J, Capela J, Fernandes H. Behaviour of co-cultured human 
osteoclastic and osteoblastic cells exposed to endodontic sealers  ’ extracts. Clin Oral Invest. 
2013;[Epub ahead of print].  
53.  Ballanti P, Minisola S, Pacitti M, Scarnecchia L, Rosso R, Mazzuoli G, Bonucci E. Tartrate-resistant 
acid phosphate activity as osteoclastic marker: sensitivity of cytochemical assessment and serum 
assay in comparison with standardized osteoclast histomorphometry. Osteoporos Int. 1997;7(1):39–
43.  
54.  JR H. Principles of Cell Proliferation. Blackwell Publishing; 2001.  
 
 
  
Effects of antihypertensive drugs in the differentiation and activation of human bone cells 
 
63 
 
Publications, communications and prizes 
 
Panel Communication  
 
 February 13 – 15, 2013 - Oliveira T, Costa-Rodrigues J, Ferraz R, Prudêncio C, 
Fernandes M H. Antihypertensive drugs and bone metatoblism: in vitro study with 
human osteoclastic cells. In IJUP’13 – 6º Encontro de Jovens Investigadores da 
Universidade do Porto 
 May 18 – 21, 2013 - Oliveira T, Costa-Rodrigues J, Ferraz R, Prudêncio C, 
Fernandes M H. Modulation of osteoclastogenesis by antihypertensive drugs. In 
Congress ECTS’13 – European Calcified Tissue Society  
 
 
